CORVUS PHARMACEUTICALS INC. - COMMON STOCK

NetDania - New 12 months High: CORVUS PHARMACEUTICALS INC. - COMMON STOCK

11 Oct 2024 10:10:42 By NetDania Notify

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

10 Sep 2024 05:30:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

03 Sep 2024 13:05:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

06 Aug 2024 13:01:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

01 Aug 2024 05:30:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024

31 Jul 2024 05:30:00 By Nasdaq GlobeNewswire

Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment of Inflammatory Diseases

25 Jul 2024 05:30:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference

30 May 2024 13:02:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

06 May 2024 13:01:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024

02 May 2024 13:02:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering

02 May 2024 05:30:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

09 Apr 2024 13:01:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

19 Mar 2024 13:02:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024

13 Mar 2024 13:02:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

12 Feb 2024 05:30:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma

08 Feb 2024 13:05:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer

06 Feb 2024 13:05:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell

23 Jan 2024 14:00:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial

09 Dec 2023 09:00:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results

07 Nov 2023 13:01:00 By Nasdaq GlobeNewswire